SCHEMBL24654075

SCHEMBL24654075

CC(C)CCCNC(=O)C(C)(C)CO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.39
KCNH2 Q12809 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
KISS1R Q969F8 1/20 0.36
EPHX1 P07099 2/20 0.34
TP53 P04637 1/20 0.34
CNR1 P21554 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
BLM P54132 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23734275 0.89 ANPEP (0.41) PTGS1KCNH2MEN1KMT2AGAA
SCHEMBL21533856 0.82 POLB (0.47) MEN1KMT2AGAASMN1; SMN2POLB
SCHEMBL23267793 0.81 MEN1 (0.38) KCNH2MEN1KMT2AGAASMN1; SMN2
SCHEMBL13446740 0.79 EPHX1 (0.43) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL618269 0.79 EPHX1 (0.50) EPHX1CNR1
SCHEMBL23770334 0.77 POLB (0.46) MEN1KMT2AGAASMN1; SMN2POLB
SCHEMBL12282931 0.77 TDP1 (0.55) PTGS1KCNH2MEN1KMT2ASMN1; SMN2
SCHEMBL29306578 0.77 EPHX1 (0.58) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL20087451 0.77 ALDH1A1 (0.65) MEN1KMT2AGAASMN1; SMN2POLB
SCHEMBL12565693 0.76 CNR1 (0.46) PTGS1KCNH2MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed
WO-2022204288-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS PLTP, LNPK, PLIN3 PTGS1 2216/4885KCNH2 4669/4885MEN1 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.